Niigata, Japan
Niigata, Japan

Niigata University is a national university in Niigata, Niigata Prefecture, Japan. It was established in 1949 and has its major origins in Niigata Medical College and in Niigata Higher School . It is one of the largest Japanese national universities on the Sea of Japan.The university comprises nine faculties and seven graduate schools . The student enrollment is about 12,000.The faculties, graduate schools are concentrated in Ikarashi Campus to the west of the city. The medical faculties are located in Asahimachi Campus in the downtown. Attached schools are located in Nishi Ohata district next to Asahimachi Campus . In a building next to Niigata Station there is a small campus named Tokimate , whose main purpose is to offer courses of lifelong learning for adults. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Niigata University | Date: 2015-04-23

A heat receiver, a reactor, and a heater utilize the heat of concentrated solar light for thermal decomposition and/or chemical reaction of coals, etc. The heat receiver includes: a side portion forming a substantially cylindrical side surface; a substantially circular bottom portion connected to the lower edge of the side portion; and a ceiling connected to the upper edge of the side portion. A substantially circular aperture is formed in the center of the ceiling. The heat receiver has a substantially cylindrical cavity and the opening portion is open. When the cavity has a diameter of D and a length of L, and the aperture has a diameter of d, d=D/2 or less and L=2D or more. Concentrated solar light entering the heat receiver is to be contained in the heat receiver to effectively utilize the solar light.


Patent
Niigata University, Juntendo Educational Foundation and Denka Seiken Co. | Date: 2017-01-09

Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly.


Patent
Niigata University, Juntendo Educational Foundation and Denka Seiken Co. | Date: 2017-01-09

Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin.


Patent
Stelic Institute & Co. and Niigata University | Date: 2016-08-19

The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.


Patent
Stelic Institute & Co. and Niigata University | Date: 2016-06-22

It is intended to provide a method which comprises administering a physiologically active substance to a target submucosal tissue and thus fixing and expressing the physiologically active substance specifically to the tissue. It has been found out that when a physiologically active substance is directly administered to a submucosal tissue without using a carrier, the physiologically active substance is safely and effectively fixed to the administration site over a long time without disappearing or diffusing and, moreover, plays a reservoir-like role to thereby exert its effect. It has been also found out that the physiologically active substance having been administered in the above-described manner would not affect organs other than the organ to which it is to be administered, thereby exerting a therapeutic effect.


Patent
EA Pharma Co. and Niigata University | Date: 2016-07-21

The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof


Patent
EA Pharma Co. and Niigata University | Date: 2016-11-30

The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof


Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia (ATL), and the viral oncoprotein Tax plays key roles in the immortalization of human T cells, lifelong persistent infection, and leukemogenesis. We herein identify the ubiquitin-specific protease 10 (USP10) as a Tax-interactor in HTLV-1-infected T cells. USP10 is an antistress factor against various environmental stresses, including viral infections and oxidative stress. On exposure to arsenic, an oxidative stress inducer, USP10 is recruited into stress granules (SGs), and USP10-containing SGs reduce reactive oxygen species (ROS) production and inhibit ROS-dependent apoptosis. We found that interaction of Tax with USP10 inhibits arsenic-induced SG formation, stimulates ROS production, and augments ROS-dependent apoptosis in HTLV-1-infected T cells. These findings suggest that USP10 is a host factor that inhibits stress-induced ROS production and apoptosis in HTLV-1-infected T cells; however, its activities are attenuated by Tax. A clinical study showed that combination therapy containing arsenic is effective against some forms of ATL. Therefore, these findings may be relevant to chemotherapy against ATL.


Yukawa M.,Niigata University
IEEE Transactions on Signal Processing | Year: 2012

This paper exemplifies that the use of multiple kernels leads to efficient adaptive filtering for nonlinear systems. Two types of multikernel adaptive filtering algorithms are proposed. One is a simple generalization of the kernel normalized least mean square (KNLMS) algorithm , adopting a coherence criterion for dictionary designing. The other is derived by applying the adaptive proximal forward-backward splitting method to a certain squared distance function plus a weighted block l 1 norm penalty, encouraging the sparsity of an adaptive filter at the block level for efficiency. The proposed multikernel approach enjoys a higher degree of freedom than those approaches which design a kernel as a convex combination of multiple kernels. Numerical examples show that the proposed approach achieves significant gains particularly for nonstationary data as well as insensitivity to the choice of some design-parameters. © 1991-2012 IEEE.


Patent
Niigata University | Date: 2016-07-13

Provided is a method for producing ambrein, comprising reacting tetraprenyl--curcumene cyclase with 3-deoxyachilleol A to obtain ambrein.

Loading Niigata University collaborators
Loading Niigata University collaborators